XML 20 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net income $ 2,780 $ 9,680
Adjustments to reconcile net income to net cash (used) provided by operating activities:    
Depreciation 5,303 5,438
Amortization of intangibles 38,217 36,159
Operating lease expense 5,389 5,570
Amortization of prepaid product discounts 8,513 8,924
Deferred income taxes (6,934) (7,524)
Employee share-based compensation expense 5,866 8,142
Other non-cash items, net 10,573 8,213
Changes in assets and liabilities:    
Trade accounts receivable (18,355) 12,248
Inventories and supplies (2,972) (893)
Other current assets 5,019 (12,731)
Payments for cloud computing arrangement implementation costs (3,701) (6,391)
Other non-current assets (5,521) (3,082)
Accounts payable 5,193 (5,003)
Prepaid product discount payments (7,383) (7,859)
Other accrued and non-current liabilities (48,693) (16,626)
Net cash (used) provided by operating activities (6,706) 34,265
Cash flows from investing activities:    
Purchases of capital assets (25,518) (20,844)
Other 34 515
Net cash used by investing activities (25,484) (20,329)
Cash flows from financing activities:    
Proceeds from issuing long-term debt and swingline loans 217,500 146,500
Payments on long-term debt and swingline loans (175,938) (137,938)
Net change in customer funds obligations (145,621) (99,240)
Employee taxes paid for shares withheld (2,034) (4,161)
Cash dividends paid to shareholders (13,616) (13,317)
Other (2,579) (1,812)
Net cash used by financing activities (122,288) (109,968)
Effect of exchange rate change on cash, cash equivalents, restricted cash and restricted cash equivalents 612 1,320
Net change in cash, cash equivalents, restricted cash and restricted cash equivalents (153,866) (94,712)
Cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of year 337,415 285,491
Cash, cash equivalents, restricted cash and restricted cash equivalents, end of period $ 183,549 $ 190,779